SCHEMBL31146116

SCHEMBL31146116

Cc1c(C(F)(F)C(=O)N[C@H](C)c2ncc(C#N)cc2F)c(=O)[nH]c2ccnc(C#N)c12

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ S1PR3 Q99500 3/20 0.33
▸ BDKRB1 P46663 4/20 0.32
▸ KIT P10721 1/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ EGLN1 Q9GZT9 2/20 0.30
▸ LRRK2 Q5S007 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31145872 1.00 S1PR3 (0.33) S1PR3BDKRB1KITPDPK1EGLN1
SCHEMBL31146259 0.93 S1PR3 (0.33) S1PR3BDKRB1KITPDPK1EGLN1
SCHEMBL31146191 0.93 S1PR3 (0.33) S1PR3BDKRB1KITPDPK1EGLN1
SCHEMBL31146144 0.84 KIT (0.36) S1PR3BDKRB1KITPDPK1
SCHEMBL31145865 0.84 KIT (0.36) S1PR3BDKRB1KITPDPK1
SCHEMBL31146199 0.78 B3GNT2 (0.33) EGLN1
SCHEMBL31145947 0.78 B3GNT2 (0.33) EGLN1
SCHEMBL31145833 0.76 S1PR3 (0.35) S1PR3BDKRB1KITPDPK1LRRK2
SCHEMBL31146187 0.76 S1PR3 (0.35) S1PR3BDKRB1KITPDPK1LRRK2
SCHEMBL31146095 0.75 PLCG1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A S1PR3 4572/4885BDKRB1 2223/4885KIT 4199/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A S1PR3 4572/4885BDKRB1 2223/4885KIT 4199/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 S1PR3 1054/4885BDKRB1 2493/4885KIT 4407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback